研究所

トップページ研究所研究分野紹介腫瘍免疫制御トランスレーショナルリサーチ分野業績

腫瘍免疫制御トランスレーショナルリサーチ分野 業績

原著論文

  1. Kuroda H, Sugita Y, Masago K, Takahashi Y, Nakada T, Sasaki E, Sakakura N, Yamaguchi R, Matsushita H, Hida T. Clinical Guideline-Guided Outcome Consistency for Surgically Resected Stage III Non-Small Cell Lung Cancer: A Retrospective Study. Cancers (Basel).;13(11):2531. 2021
  2. Shigenobu T, Takahashi Y, Masugi Y, Hanawa R, Matsushita H, Tajima A, Kuroda H. Micropapillary Predominance Is a Risk Factor for Brain Metastasis in Resected Lung Adenocarcinoma. Clin Lung Cancer.: S1525-7304(21)00085-1. 2021
  3. Sato Y, Mori K, Hirano K, Yagi K, Kobayashi Y, Nagaoka K, Hosoi A, Matsushita H, Kakimi K, Seto Y. Adoptive γδT-cell transfer alone or combined with chemotherapy for the treatment of advanced esophageal cancer. Cytotherapy.; 23(5):423-432. 2021
  4. Takahashi Y, Suzuki S, Hamada K, Nakada T, Oya Y, Sakakura N, Matsushita H, Kuroda H. Sarcopenia is poor risk for unfavorable short- and long-term outcomes in stage I non-small cell lung cancer. Ann Transl Med.; 9(4):325. 2021
  5. Matsui T, Takahashi Y, Nakada T, Matsushita H, Oya Y, Sakakura N, Kuroda H. Efficacy of Xenon Light With Indocyanine Green for Intersegmental Visibility in Thoracoscopic Segmentectomy. J Surg Res.;259:39-46. 2021
  6. Yabuno A, Matsushita H, Hamano T, Tan TZ, Shintani D, Fujieda N, Tan DSP, Huang RY, Fujiwara K, Kakimi K, Hasegawa K. Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma. .Sci Rep. ;10(1):18503. 2020
  7. Sato Y, Wada I, Odaira K, Hosoi A, Kobayashi Y, Nagaoka K, Karasaki T, Matsushita H, Yagi K, Yamashita H, Fujita M, Watanabe S, Kamatani T, Miya F, Mineno J, Nakagawa H, Tsunoda T, Takahashi S, Seto Y, Kakimi K.Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells. Clin Transl Immunology. ;9(10):e1194. 2020
  8. Kakimi K, Matsushita H, Masuzawa K, Karasaki T, Kobayashi Y, Nagaoka K, Hosoi A, Ikemura S, Kitano K, Kawada I, Manabe T, Takehara T, Ebisudani T, Nagayama K, Nakamura Y, Suzuki R, Yasuda H, Sato M, Soejima K, Nakajima JAdoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study. .J Immunother Cancer.;8(2):e001185. 2020
  9. Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, Yabuno A, Nishijima A, Nejo T, Kobayashi Y, Sato S, Ikeda Y, Miyai M, Takahashi Y, Yamaguchi R, Fujiwara K, Aburatani H, Kakimi K. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. J Immunother Cancer. 8(1):e000375. 2020
  10. Kobayashi Y, Yamada D, Kawai T, Sato Y, Teshima T, Yamada Y, Nakamura M, Suzuki M, Matsumoto A, Nakagawa T, Hosoi A, Nagaoka K, Karasaki T, Matsushita H, Kume H, Kakimi K. Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma. Int J Oncol. 56(4):999-1013. 2020
  11. Nejo T, Matsushita H, Karasaki T, Nomura M, Saito K, Tanaka S, Takayanagi S, Hana T, Takahashi S, Kitagawa Y, Koike T, Kobayashi Y, Nagae G, Yamamoto S, Ueda H, Tatsuno K, Narita Y, Nagane M, Ueki K, Nishikawa R, Aburatani H, Mukasa A, Saito N, Kakimi K. Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma. Cancer Immunol Res. 7(7):1148-1161. 2019
  12. Ohue Y, Kurose K, Karasaki T, Isobe M, Yamaoka T, Futami J, Irei I, Masuda T, Fukuda M, Kinoshita A, Matsushita H, Shimizu K, Nakata M, Hattori N, Yamaguchi H, Fukuda M, Nozawa R, Kakimi K, Oka M. Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC. J Thorac Oncol. 14(12):2071-2083. 2019
  13. Emoto K, Eguchi T, Tan KS, Takahashi Y, Aly RG, Rekhtman N, Travis WD, Adusumilli PS. Expansion of the Concept of Micropapillary Adenocarcinoma to Include a Newly Recognized Filigree Pattern as Well as the Classical Pattern Based on 1468 Stage I Lung Adenocarcinomas. J Thorac Oncol 14(11):1948-1961. 2019
  14. Aly RG, Rekhtman N, Li X, Takahashi Y, Eguchi T, Tan KS, Rudin CM, Adusumilli PS, Travis WD. Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. J Thorac Oncol 14(9):1583-1593. 2019
  15. Takahashi Y, Suzuki S, Matsutani N, Kawamura M. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node-negative non-small cell lung cancer. Thorac Cancer 10(3):413-420. 2019
  16. Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronne L, Kogure Y, Sato Y, Nishida K, Gion Y, Shiraishi Y, Tanaka H, Chiba K, Watatani Y, Kakiuchi N, Shiozawa Y, Yoshizato T, Yoshida K, Makishima H, Sanada M, Onozawa M, Teshima T, Yoshiki Y, Ishida T, Suzuki K, Shimada K, Tomita A, Kato M, Ota Y, Izutsu K, Demachi-Okamura A, Akatsuka Y, Miyano S, Yoshino T, Gaulard P, Hermine O, Takeuchi K, Ohshima K, Ogawa S. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 33(7):1687-1699. 2019
  17. Ohta R, Demachi-Okamura A, Akatsuka Y, Fujiwara H, Kuzushima K. Improving TCR affinity on 293T cells. J Immunol Methods. 466:1-8. 2019
  18. Imai Y, Hasegawa K, Matsushita H, Fujieda N, Sato S, Miyagi E, Kakimi K, Fujiwara K. Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma. Oncol Lett. 15(5):6457-6468. 2018
  19. Yamamoto M, Nomura S, Hosoi A, Nagaoka K, Iino T, Yasuda T, Saito T, Matsushita H, Uchida E, Seto Y, Goldenring JR, Kakimi K, Tatematsu M, Tsukamoto T.　Established gastric cancer cell lines transplantable into C57BL/6 mice demonstrate FGFR4 promotion of tumor growth.　Cancer Sci. 109(5):1480-1492. 2018.
  20. Nagaoka K, Hosoi A, Iino T, Morishita Y, Matsushita H, Kakimi K. Dendritic cell vaccine induces antigen-specific CD8+ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade. Oncoimmunology. 7(3):e1395124. 2017
  21. Hosoi A, Takeda K, Nagaoka K, Iino T, Matsushita H, Ueha S, Aoki S, Matsushima K, Kubo M, Morikawa T, Kitaura K, Suzuki R, Kakimi K. Increased diversity with reduced “diversity evenness” of tumor infiltrating T-cells for the successful cancer immunotherapy. Sci Rep. 8(1):1058. 2018
  22. Hoshikawa M, Aoki T, Matsushita H, Karasaki T, Hosoi A, Odaira K, Fujieda N, Kobayashi Y, Kambara K, Ohara O, Arita J, Hasegawa K, Kakimi K, Kokudo N.NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. Biochem Biophys Res Commun. 495(2):2058-2065. 2018
  23. Matsushita H, Hasegawa K, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Karasaki T, Fujiwara K, Aburatani H, Kakimi K. The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. Oncoimmunology. 6(8):e1338996. 2017
  24. Aoki T, Matsushita H, Hoshikawa M, Hasegawa K, Kokudo N, Kakimi K. Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer. Cytotherapy. 19(4):473-485. 2017
  25. Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y, Kashiwabara K, Takazawa M, Ohara O, Kakimi K, Nakajima J. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. J Thorac Oncol. 12(5):791-803. 2017
  26. Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Takazawa M, Ohara O, Nakajima J, Kakimi K. Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing. Cancer Sci. 108(2):170-177. 2017
  27. Odaira K, Kimura SN, Fujieda N, Kobayashi Y, Kambara K, Takahashi T, Izumi T, Matsushita H, Kakimi K. CD27(-)CD45(+) γδ T cells can be divided into two populations, CD27(-)CD45(int) and CD27(-)CD45(hi) with little proliferation potential. Biochem Biophys Res Commun. 478(3):1298-303. 2016
  28. Matsushita H, Sato Y, Karasaki T, Nakagawa T, Kume H, Ogawa S, Homma Y, Kakimi K. Neoantigen load, antigen presentation machinery, and immune signatures determine prognosis in clear cell renal cell carcinoma. Cancer Immunol Res. 4(5): 463-71. 2016
  29. Makise N, Morikawa T, Nakagawa T, Ichimura T, Kawai T, Matsushita H, Kakimi K, Kume H, Homma Y, Fukayama M. MAGE-A expression, immune microenvironment, and prognosis in upper urinary tract carcinoma. Hum Pathol. 50:62-9. 2016
  30. Karasaki T, Nagayama K, Kawashima M, Hiyama N, Murayama T, Kuwano H, Nitadori JI, Anraku M, Sato M, Miyai M, Hosoi A, Matsushita H, Kikugawa S, Matoba R, Ohara O, Kakimi K, Nakajima J.　Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer. J Thorac Oncol. 11(3):324-333. 2015
  31. Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, Maekawa R, Matsushima K, Ohara O, Kakimi K. Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNγ-dependent cell-cycle arrest. Cancer Immunol Res. Jan;3(1):26-36. 2015
  32. Futami J, Nonomura H, Kido M, Niidoi N, Fujieda N, Hosoi A, Fujita K, Mandai K, Atago Y, Kinoshita R, Honjo T, Matsushita H, Uenaka A, Nakayama E, Kakimi K. Sensitive Multiplexed Quantitative Analysis of Autoantibodies to Cancer Antigens with Chemically S-Cationized Full-Length and Water-Soluble Denatured Proteins. Bioconjug Chem. 26(10):2076-84. 2015
  33. Miyai M, Eikawa S, Hosoi A, Iino T, Matsushita H, Isobe M, Uenaka A, Udono H, Nakajima J, Nakayama E, Kakimi K. Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient. PLoS One. Aug 20;10(8):e0136086. 2015
  34. Hirano K, Hosoi A, Matsushita H, Iino T, Ueha S, Matsushima K, Seto Y, Kakimi K. The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy. Oncoimmunology. 4(8). 2015.
  35. Futami J, Fujiyama H, Kinoshita R, Nonomura H, Honjo T, Tada H, Matsushita H, Abe Y, Kakimi K. Denatured Mammalian protein mixtures exhibit unusually high solubility in nucleic Acid-free pure water. PLoS One. 9(11):e113295. 2014
  36. Yamada D, Matsushita H, Azuma T, Nakagawa T, Nagata M, Yamada Y, Suzuki M, Fujimura T, Fukuhara H, Kume H, Homma Y, Kakimi K. Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy. Mol Clin Oncol. 2(6):1023-1027. 2014
  37. Matsushita H, Enomoto H, Kume H, Nakagawa T, Fukuhara H, Suzuki M, Fujimura T, Homma Y and Kakimi K. A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. Journal for Immunotherapy of Cancer 2:30. 2014
  38. Kawai T, Enomoto Y, Morikawa T, Matsushita H, Kume H, Fukayama M, Yamaguchi H, Kakimi K, Homma Y. High expression of heat shock protein 105 predicts a favorable prognosis for patients with urinary bladder cancer treated with radical cystectomy.Mol Clin Oncol. 2(1):38-42. 2014
  39. Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, Shimizu N, Seto Y, Kakimi K. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med. 3(2):362-75. 2014
  40. Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E.Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. J Immunother. 37(2):84-92. 2014
  41. Ichimura T, Morikawa T, Kawai T, Nakagawa T, Matsushita H, Kakimi K, Kume H, Ishikawa S, Homma Y, Fukayama M. Prognostic significance of CD204-positive macrophages in upper urinary tract cancer. Ann Surg Oncol. Jun;21(6):2105-12. 2014
  42. Hosoi A, Matsushita H, Shimizu K, Fujii S, Ueha S, Abe J, Kurachi M, Maekawa R, Matsushima K, Kakimi K. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. Int J Cancer. Apr 15;134(8):1810-22. 2014
  43. Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, Murakawa T, Nakajima J, Matsushita H, Kakimi K. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain. Cytotherapy. Apr;15(4):481-91. 2013
  44. Shimizu K, Mizuno T, Shinga J, Asakura M, Kakimi K, Ishii Y, Masuda K, Maeda T, Sugahara H, Sato Y, Matsushita H, Nishida K, Hanada K, Dorrie J, Schaft N, Bickham K, Koike H, Ando T, Nagai R, Fujii S. Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.Cancer Res. Jan 1;73(1):62-73. 2013
  45. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 482(7385): 400-4. 2012
  46. Noji S, Hosoi A, Takeda K, Matsushita H, Morishita Y, Seto Y, Kakimi K. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy. J Immunother. Jul;35(6):460-72. 2012
  47. Kondo M, Izumi T, Fujieda N, Kondo A, Morishita T, Matsushita H, Kakimi K. Expansion of Human Peripheral Blood γδ T Cells using Zoledronate. J Vis Exp. Sep 9 ;(55) pii:3182. 2011
  48. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 208(10):1989-2003. 2011
  49. Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Takamoto S, Matsushita H, Kakimi K. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study. J Immunother. Mar;34(2):202-11. 2011
  50. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL, and Murphy KM. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 322, 1097-1100. 2008
  51. Ishida T, Obata Y, Ohara N, Matsushita H, Sato S, Uenaka A, Saika T, Miyamura T, Chayama K, Nakamura Y, Wada H, Yamashita T, Morishima T, Old LJ, Nakayama E .Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity. Cancer Immun. 8:15. 2008

総説等

  1. Shinohara S, Takahashi Y, Demachi-Okamura A, Matsushita H. Identification of neoantigens and development of antigen-specific immunotherapy. Rinsho Ketsueki; 61(9):1433-1439. 2020
  2. Takahashi Y, Kuroda H, Oya Y, Matsutani N, Matsushita H, Kawamura M. Challenges for real-time intraoperative diagnosis of high risk histology in lung adenocarcinoma: A necessity for sublobar resection. Thorac Cancer 10(8):1663-1668. 2019
  3. 高橋祐介、岡村文子、松下博和　がん抗原とT細胞による認識機構　実験医学増刊　Vol.37　No.15　p28-32 2019
  4. 松下博和、岡村文子、高橋祐介　ネオアンチゲンはがんに対するナチュラルに誘導されるあるいは治療により誘導される免疫応答の重要な標的である　癌と化学療法Vol.46　No.9　p1372-1376 2019
  5. 宮井まなみ、松下博和：がん治療における免疫療法. 保健の科学61:481-486　2019
  6. 松下博和　T細胞認識癌抗原：Shared抗原とNeo抗原 臨床免疫・アレルギー科Vol.69 No.2 p141-147 2018
  7. 松下博和　がんの免疫監視、免疫編集、そして治療へ 医学のあゆみVol.263 No.1 p21-26 2017
  8. 松下博和、唐崎隆弘、垣見和宏 宿主免疫でのネオアンチゲンの役割　遺伝子医学MOOK p151-156 2017
  9. 松下博和　免疫編集とネオ抗原の意義 炎症と免疫　Vol.25 No.3; p57-61 2017
  10. 松下博和　がんの免疫編集について教えてください がん免疫療法Vol.1 No.1; p44-45 2017
  11. 松下博和　免疫チェックポイント阻害とネオ抗原特異的T細胞 カレントテラピー Vol.35 No.2 p113-119 2017
  12. 松下博和、垣見和宏　gdT細胞用いたがん免疫治療　日本臨床　第75巻・第2号p301-305 2017
  13. 松下博和　がん免疫研究のCutting Edge-Neoantigen in cancer immunotherapy　Cancer board p482-487 2016
  14. 松下博和　がん免疫編集機構:マウスからヒトへ 実験医学増刊 Vol. 34 No.12；p92-99 2016
  15. 松下博和、唐崎隆弘、垣見和宏 ネオアンチゲンを標的としたがん免疫治療　医薬ジャーナルVol.52 No.4 p119-124 2016
  16. 松下博和　がん免疫編集機構における自然免疫系と適応免疫系の役割　実験医学増刊 Vol. 31 No.12；92-99 2013
  17. 松下博和　がん免疫編集機構　医学のあゆみ Vol. 244 No.9；739-744 2013
  18. 宮井まなみ、垣見和宏　Ｖγ9Ｖδ2Ｔ細胞を用いたがん免疫治療 医学のあゆみ 2013, Vol. 244 No. 9; 854-860
  19. 宮井まなみ、垣見和宏　がん抗原と抗体医薬 総論 がん免疫治療におけるパラダイムシフト（解説/特集）BIO Clinica(0919-8237)30巻3号 page221-223(2013.03)
  20. 垣見和宏、近藤　篤、松下博和　樹状細胞によるがん治療　日本臨床第70巻、第12号；2130-2135 2012